|
2025-04-11 |
2025-04-11 |
S
Sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
1,000
-1.3%
11.49
USD 583,692
|
1,000
-1.3%
|
11.49
|
USD 100,000
|
|
|
2025-04-11 |
2025-04-10 |
S
Sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
1,000
-1.2%
10.87
USD 543,500
|
1,000
-1.2%
|
10.87
|
USD 100,000
|
|
|
2025-04-11 |
2025-04-09 |
S
Sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
1,000
-0.0%
11.76
USD 19,016
|
1,000
-0.0%
|
11.76
|
USD 100,000
|
|
|
2025-04-11 |
2025-04-09 |
S
Sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
1,000
-0.1%
10.75
USD 36,550
|
1,000
-0.1%
|
10.75
|
USD 100,000
|
|
|
2025-04-11 |
2025-04-09 |
S
Sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
1,000
-0.9%
9.93
USD 350,579
|
1,000
-0.9%
|
9.93
|
USD 100,000
|
|
|
2025-03-17 |
2025-03-13 |
S
Sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
51,425
-1.3%
15.07
USD 774,975
|
51,425
-1.3%
|
15.07
|
USD 774,975
|
|
|
2025-03-05 |
2025-03-04 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
133,333
-3.4%
17.02
USD 2,269,328
|
133,333
-3.4%
|
17.02
|
USD 2,269,328
|
|
|
2025-03-05 |
2025-03-03 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
166,667
-4.1%
18.03
USD 3,005,006
|
166,667
-4.1%
|
18.03
|
USD 3,005,006
|
|
|
2025-01-27 |
2025-01-23 |
PS
Planned sale
|
OLUKOTUN ADEOYE Y
Non-Executive Director
|
959
-2.6%
21.00
USD 20,139
|
959
-2.6%
|
21.00
|
USD 20,139
|
|
|
2025-01-07 |
2025-01-07 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
8,000
-1.5%
19.69
USD 157,520
|
8,000
-1.5%
|
19.69
|
USD 157,520
|
|
|
2025-01-07 |
2025-01-07 |
S
Sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
10,000
-2.1%
19.69
USD 196,900
|
10,000
-2.1%
|
19.69
|
USD 196,900
|
|
|
2025-01-07 |
2025-01-07 |
PS
Planned sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
8,000
-1.7%
19.70
USD 157,600
|
8,000
-1.7%
|
19.70
|
USD 157,600
|
|
|
2025-01-07 |
2025-01-06 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
9,526
-1.7%
20.10
USD 191,473
|
9,526
-1.7%
|
20.10
|
USD 191,473
|
|
|
2025-01-07 |
2025-01-06 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
19,658
-3.5%
19.69
USD 387,066
|
19,658
-3.5%
|
19.69
|
USD 387,066
|
|
|
2025-01-07 |
2025-01-06 |
PS
Planned sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
9,402
-1.9%
20.10
USD 188,980
|
9,402
-1.9%
|
20.10
|
USD 188,980
|
|
|
2025-01-07 |
2025-01-06 |
PS
Planned sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
17,765
-3.5%
19.68
USD 349,615
|
17,765
-3.5%
|
19.68
|
USD 349,615
|
|
|
2025-01-07 |
2025-01-06 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
Officer
|
10,971
-3.9%
20.11
USD 220,627
|
10,971
-3.9%
|
20.11
|
USD 220,627
|
|
|
2025-01-07 |
2025-01-06 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
Officer
|
21,758
-7.1%
19.68
USD 428,197
|
21,758
-7.1%
|
19.68
|
USD 428,197
|
|
|
2025-01-06 |
2025-01-02 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
11,520
-0.3%
19.05
USD 219,456
|
11,520
-0.3%
|
19.05
|
USD 219,456
|
|
|
2024-12-30 |
2024-12-27 |
PS
Planned sale
|
OLUKOTUN ADEOYE Y
Non-Executive Director
|
2,850
-7.2%
20.00
USD 57,000
|
2,850
-7.2%
|
20.00
|
USD 57,000
|
|
|
2024-12-23 |
2024-12-23 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
12,563
-0.3%
19.59
USD 246,109
|
12,563
-0.3%
|
19.59
|
USD 246,109
|
|
|
2024-12-20 |
2024-12-18 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
5,799
-0.2%
22.12
USD 128,274
|
5,799
-0.2%
|
22.12
|
USD 128,274
|
|
|
2024-12-20 |
2024-12-18 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
8,260
-0.2%
21.74
USD 179,572
|
8,260
-0.2%
|
21.74
|
USD 179,572
|
|
|
2024-12-20 |
2024-12-18 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
12,653
-0.3%
20.52
USD 259,640
|
12,653
-0.3%
|
20.52
|
USD 259,640
|
|
|
2024-12-18 |
2024-12-17 |
PS
Planned sale
|
GIVEN DOUGLAS B
Non-Executive Director
|
547
-0.4%
22.04
USD 12,056
|
547
-0.4%
|
22.04
|
USD 12,056
|
|
|
2024-12-18 |
2024-12-17 |
PS
Planned sale
|
Waddill William D.
Non-Executive Director
|
3,747
-8.5%
22.04
USD 82,584
|
3,747
-8.5%
|
22.04
|
USD 82,584
|
|
|
2024-12-18 |
2024-12-16 |
PS
Planned sale
|
GIVEN DOUGLAS B
Non-Executive Director
|
5,000
-3.9%
21.90
USD 109,500
|
5,000
-3.9%
|
21.90
|
USD 109,500
|
|
|
2024-12-18 |
2024-12-16 |
PS
Planned sale
|
Vakiener Victoria
Non-Executive Director
|
8,994
-29.8%
21.91
USD 197,059
|
8,994
-29.8%
|
21.91
|
USD 197,059
|
|
|
2024-12-18 |
2024-12-16 |
PS
Planned sale
|
Waddill William D.
Non-Executive Director
|
3,748
-7.8%
21.90
USD 82,081
|
3,748
-7.8%
|
21.90
|
USD 82,081
|
|
|
2024-07-03 |
2024-07-02 |
PS
Planned sale
|
Oliver Tracie
Chief Commercial Officer
Officer
|
9,394
-6.9%
25.28
USD 237,480
|
9,394
-6.9%
|
25.28
|
USD 237,480
|
|
|
2024-05-06 |
2024-05-02 |
PS
Planned sale
|
Vakiener Victoria
Non-Executive Director
|
1,799
-5.6%
23.31
USD 41,935
|
1,799
-5.6%
|
23.31
|
USD 41,935
|
|
|
2024-04-03 |
2024-04-01 |
S
Sale
|
Hamilton James C
Chief Discovery/Trans Medicine
Officer
|
6,000
-2.8%
28.03
USD 168,180
|
6,000
-2.8%
|
28.03
|
USD 168,180
|
|
|
2024-03-20 |
2024-03-20 |
B
Purchase
|
Lu Hongbo
Non-Executive Director
|
1,000
+3.1%
27.50
USD 27,500
|
1,000
+3.1%
|
27.50
|
USD 27,500
|
|
|
2024-03-20 |
2024-03-19 |
B
Purchase
|
Lu Hongbo
Non-Executive Director
|
1,000
+3.2%
28.00
USD 28,000
|
1,000
+3.2%
|
28.00
|
USD 28,000
|
|
|
2024-03-20 |
2024-03-18 |
B
Purchase
|
Lu Hongbo
Non-Executive Director
|
1,000
+3.3%
27.49
USD 27,490
|
1,000
+3.3%
|
27.49
|
USD 27,490
|
|
|
2024-03-08 |
2024-03-06 |
S
Sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
40,000
-9.1%
35.19
USD 1,407,600
|
40,000
-9.1%
|
35.19
|
USD 1,407,600
|
|
|
2024-02-02 |
2024-01-31 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
19,730
-0.5%
32.71
USD 645,368
|
19,730
-0.5%
|
32.71
|
USD 645,368
|
|
|
2024-02-02 |
2024-01-31 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
37,769
-1.0%
32.16
USD 1,214,651
|
37,769
-1.0%
|
32.16
|
USD 1,214,651
|
|
|
2024-01-17 |
2024-01-12 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
Officer
|
3,702
-1.7%
37.37
USD 138,344
|
3,702
-1.7%
|
37.37
|
USD 138,344
|
|
|
2024-01-17 |
2024-01-12 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
Officer
|
4,238
-1.9%
36.47
USD 154,560
|
4,238
-1.9%
|
36.47
|
USD 154,560
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
Vakiener Victoria
Non-Executive Director
|
1,100
-3.3%
38.84
USD 42,724
|
1,100
-3.3%
|
38.84
|
USD 42,724
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
Vakiener Victoria
Non-Executive Director
|
3,620
-9.9%
37.87
USD 137,089
|
3,620
-9.9%
|
37.87
|
USD 137,089
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
Ferrari Mauro
Non-Executive Director
|
1,000
-1.6%
38.63
USD 38,630
|
1,000
-1.6%
|
38.63
|
USD 38,630
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
Ferrari Mauro
Non-Executive Director
|
2,147
-3.4%
37.80
USD 81,157
|
2,147
-3.4%
|
37.80
|
USD 81,157
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
GIVEN DOUGLAS B
Non-Executive Director
|
1,100
-0.8%
38.55
USD 42,405
|
1,100
-0.8%
|
38.55
|
USD 42,405
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
GIVEN DOUGLAS B
Non-Executive Director
|
1,811
-1.4%
37.76
USD 68,383
|
1,811
-1.4%
|
37.76
|
USD 68,383
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
Waddill William D.
Non-Executive Director
|
1,300
-2.6%
38.59
USD 50,167
|
1,300
-2.6%
|
38.59
|
USD 50,167
|
|
|
2024-01-16 |
2024-01-11 |
PS
Planned sale
|
Waddill William D.
Non-Executive Director
|
2,634
-5.1%
37.81
USD 99,592
|
2,634
-5.1%
|
37.81
|
USD 99,592
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
San Martin Javier
Chief Medical Officer
Officer
|
4,403
-2.2%
35.64
USD 156,923
|
4,403
-2.2%
|
35.64
|
USD 156,923
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
San Martin Javier
Chief Medical Officer
Officer
|
3,100
-1.5%
35.03
USD 108,593
|
3,100
-1.5%
|
35.03
|
USD 108,593
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
San Martin Javier
Chief Medical Officer
Officer
|
800
-0.4%
34.11
USD 27,288
|
800
-0.4%
|
34.11
|
USD 27,288
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
Oliver Tracie
Chief Commercial Officer
Officer
|
74
-0.1%
33.89
USD 2,508
|
74
-0.1%
|
33.89
|
USD 2,508
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
8,904
-2.0%
35.65
USD 317,428
|
8,904
-2.0%
|
35.65
|
USD 317,428
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
5,800
-1.3%
34.97
USD 202,826
|
5,800
-1.3%
|
34.97
|
USD 202,826
|
|
|
2024-01-08 |
2024-01-05 |
PS
Planned sale
|
Myszkowski Kenneth Allen
Chief Financial Officer
Officer
|
1,400
-0.3%
34.04
USD 47,656
|
1,400
-0.3%
|
34.04
|
USD 47,656
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
12,741
-2.7%
35.65
USD 454,217
|
12,741
-2.7%
|
35.65
|
USD 454,217
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
8,200
-1.7%
34.99
USD 286,918
|
8,200
-1.7%
|
34.99
|
USD 286,918
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
1,900
-0.4%
33.99
USD 64,581
|
1,900
-0.4%
|
33.99
|
USD 64,581
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
10,000
-4.4%
35.00
USD 350,000
|
10,000
-4.4%
|
35.00
|
USD 350,000
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
12,343
-5.1%
35.65
USD 440,028
|
12,343
-5.1%
|
35.65
|
USD 440,028
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
8,000
-3.2%
34.94
USD 279,520
|
8,000
-3.2%
|
34.94
|
USD 279,520
|
|
|
2024-01-05 |
2024-01-05 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
1,800
-0.7%
34.00
USD 61,200
|
1,800
-0.7%
|
34.00
|
USD 61,200
|
|
|
2024-01-05 |
2024-01-04 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
1,600
-0.4%
32.63
USD 52,208
|
1,600
-0.4%
|
32.63
|
USD 52,208
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
1,700
-0.4%
32.65
USD 55,505
|
1,700
-0.4%
|
32.65
|
USD 55,505
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
400
-0.1%
33.41
USD 13,364
|
400
-0.1%
|
33.41
|
USD 13,364
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
2,800
-0.7%
32.52
USD 91,056
|
2,800
-0.7%
|
32.52
|
USD 91,056
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
O'Brien Patrick
COO and General Counsel
Officer
|
3,849
-0.9%
31.83
USD 122,514
|
3,849
-0.9%
|
31.83
|
USD 122,514
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
500
-0.3%
33.30
USD 16,650
|
500
-0.3%
|
33.30
|
USD 16,650
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
2,300
-1.3%
32.52
USD 74,796
|
2,300
-1.3%
|
32.52
|
USD 74,796
|
|
|
2024-01-05 |
2024-01-03 |
PS
Planned sale
|
Hamilton James C
Chief Discovery/Trans Medicine
|
3,500
-1.9%
31.81
USD 111,335
|
3,500
-1.9%
|
31.81
|
USD 111,335
|
|
|
2024-01-04 |
2024-01-02 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
5,318
-0.1%
31.25
USD 166,188
|
5,318
-0.1%
|
31.25
|
USD 166,188
|
|
|
2024-01-04 |
2024-01-02 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
4,634
-0.1%
30.74
USD 142,449
|
4,634
-0.1%
|
30.74
|
USD 142,449
|
|
|
2023-12-22 |
2023-12-20 |
PS
Planned sale
|
Anzalone Christopher Richard
Chief Executive Officer
Executive Director
|
12,000
-0.3%
28.54
USD 342,480
|
12,000
-0.3%
|
28.54
|
USD 342,480
|
|
|
2023-11-22 |
2023-11-20 |
S
Sale
|
San Martin Javier
Chief Medical Officer
Officer
|
4,942
-3.6%
29.00
USD 143,318
|
4,942
-3.6%
|
29.00
|
USD 143,318
|
|
|
2023-11-22 |
2023-11-20 |
S
Sale
|
San Martin Javier
Chief Medical Officer
Officer
|
14,758
-9.7%
28.73
USD 423,997
|
14,758
-9.7%
|
28.73
|
USD 423,997
|
|
